
Chinese global pharmaceutical firm, Yisheng Biopharma Co., Ltd. met with the Philippine Board of Investments (BOI) on May 11, 2022 to discuss the company’s plan to pursue investment interests in clinical trials and the opportunity for co-development/manufacturing and marketing of vaccines with a local company in the Philippines.